Skip to content

The role of Thalidomide in Reversing Cachexia in Patients with Oesophageal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN45162540
Enrollment
12
Registered
2006-09-29
Start date
2003-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Oesophageal Cancer Oesophageal

Interventions

Thalidomide will be prescribed strictly in accordance with the regulations laid down by S.T.E.P.S. (System for Thalidomide Education & Prescribing Safety). Patients will be established on an isocalori
quality of life questionnaire (Karnofsky Index), nutritional status, and a detailed neurological examination will be conducted to look for evidence of neurotoxicity. Sensory nerve action potential amp

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 12 oesophageal cancer patients will be recruited from the endoscopy database. Inclusion criteria: 1. Patients with non obstructing and inoperable oesophageal cancer 2. Able to swallow a semi solid diet (Dysphagia score <3)

Exclusion criteria

Exclusion criteria: 1. Pre menopausal women 2. Patients receiving any adjuvant chemo or radiotherapy 3. Patients with oesophageal obstruction 4. Patients with established neuropathy 5. Patients requiring frequent laser ablation sessions 6. Patients unable to take a constant calorific intake 7. Increased debility

Design outcomes

Primary

MeasureTime frame
Reduction in metabolic rate, weight gain and improvement in quality of life.

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026